Earl, H. M., Hiller, L., Dunn, J. A., Blenkinsop, C., Grybowicz, L., Vallier, A., . . . Hayward, R. L. (2017). Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial. Ann Oncol.
Παραπομπή Chicago StyleEarl, H. M., et al. "Disease-free and Overall Survival At 3.5 Years for Neoadjuvant Bevacizumab Added to Docetaxel Followed By Fluorouracil, Epirubicin and Cyclophosphamide, for Women With HER2 Negative Early Breast Cancer: ARTemis Trial." Ann Oncol 2017.
Παραπομπή MLAEarl, H. M., et al. "Disease-free and Overall Survival At 3.5 Years for Neoadjuvant Bevacizumab Added to Docetaxel Followed By Fluorouracil, Epirubicin and Cyclophosphamide, for Women With HER2 Negative Early Breast Cancer: ARTemis Trial." Ann Oncol 2017.